{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-042466","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-09-14T10:15:26+00:00","discovered_at":"2026-09-14T10:20:00.746679+00:00","generated_at":"2026-09-14T10:20:10.933984+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lipocine initiates BLOOM Phase 3 of LPCN 1154 for postpartum depression","bullets":["BLOOM to enroll ~120 patients with severe PPD; first dosing expected early Q4 2026.","Prior Phase 3 missed primary endpoint; post hoc analysis excluded one site with ~40% undetectable drug.","No treatment-related severe/serious AEs or excessive sedation in prior Phase 3.","Company has $23.3M cash (6/30/26); expects ~$1M/month cash use during study.","Study incorporates FDA feedback and strengthened site quality controls."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-042466","json":"https://secwatch.observer/filing/0001493152-26-042466.json","markdown":"https://secwatch.observer/filing/0001493152-26-042466.md","text":"https://secwatch.observer/filing/0001493152-26-042466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226042466/0001493152-26-042466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226042466/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-14T10:20:10.933984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}